CONy 2022 | The clinical benefit of safinamide in treating Parkinson’s disease

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, talks on using safinamide, a reversible MAO B-inhibitor in the treatment of Parkinson’s disease. Patients on typical medication of the same class may experience pain, depression and anxiety during off periods and safinamide has demonstrated to be a suitable alternative to reversible MAO B-inhibitors such as selegiline and rasagiline. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.